SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

  • Post author:
  • Post category:News

SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® Positive results show Pentarlandir is safe and effective in patients with mild-to-moderate COVID-19 Press Release…

Continue ReadingSyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

  • Post author:
  • Post category:News

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01) Early research suggests Pentarlandir is safe to use against COVID-19; Phase 3 trial evaluating…

Continue ReadingSyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

Q&A with SyneuRx Chief Scientist and CEO., Emil Tsai, M.D.–Ph.D., M.A.S.: What are the top Symptoms of the BA.2 Variant and is it a Major Cause for Concern?

  • Post author:
  • Post category:Blog

Q&A with SyneuRx Chief Scientist and CEO, Dr. Emil Tsai: What Are The Top Symptoms of The BA.2 Variant and Is It a Major Cause of Concern? Since the beginning…

Continue ReadingQ&A with SyneuRx Chief Scientist and CEO., Emil Tsai, M.D.–Ph.D., M.A.S.: What are the top Symptoms of the BA.2 Variant and is it a Major Cause for Concern?

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants

  • Post author:
  • Post category:News

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants Acting as Both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir® is…

Continue ReadingSyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants

SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing

  • Post author:
  • Post category:News

SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir® Has Entered Final Portion of FDA Phase II Testing Based on Highly-Purified Isomers of Tannic Acid and Acting as a Dual…

Continue ReadingSyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing